CD274 and urinary bladder cancer: Despite the successful introduction of various checkpoint inhibitors in bladder cancer, the objective response rate (ORR) is limited, and lies within 46.4% ORR in programed death –ligand 1 (PD-L1) positive [2] and between 0% and 26.2% ORR in PD-L1 negative patients [2–3].